Merck Drives New Innovation & Adds Capacity to Advance Next Generation Antibody-drug Conjugate (ADC) Therapies
– Merck’s unique technology, ChetoSensar™, gives new promise to ADCs by alleviating solubility challenges – New DOLCORE™ platform increases speed-to-market by up to a year – Expanded ADC clinical manufacturing facility drives next generation ADCs, building on company’s 15 years of ADC Contract Development Manufacturing Organization (CDMO) experience – Reinforces company’s ambition to accelerate growth…